Research ReportsAurobindo Pharma Q1 Results Review - Margins On Course For Gradual Improvement: ICICI Securities
ADVERTISEMENT
Aurobindo Pharma Q1 Results Review - Margins On Course For Gradual Improvement: ICICI Securities
Company's US sales moderated on account of seasonality in its OTC portfolio; besides, the supplies from Eugia unit 3 were benign & sales of gRevlimid were also flat sequentially, says the brokerage
Aurobindo Pharma's manufacturing facility. (Source: Company website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.